Patient-initiated DMARD self-monitoring service not cost effective
- PDF / 170,702 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 97 Downloads / 243 Views
PharmacoEconomics & Outcomes News 860, p26 - 22 Aug 2020 Patient-initiated DMARD self-monitoring service not cost effective A patient-initiated disease-modifying antirheumatic drug (DMARD) self-monitoring service does not appear to be cost effective compared with usual care, according to findings of a study published in Rheumatology. Investigators performed an economic analysis alongside a single-centre, randomised controlled trial comparing the effectiveness and costs of a patient-initiated DMARD self-monitoring service versus usual care in 100 patients with rheumatoid arthritis or psoriatic arthritis who had been on stable treatment with methotrexate for 6 months or longer. The cost effectiveness of the service was assessed from the perspective of the UK National Health Service (NHS). Healthcare costs in patients randomised to the DMARD self-monitoring service were significantly greater than with usual care when telephone helpline costs were included in the service (£1029 vs £766 per patient [British pounds]; p
Data Loading...
